EXCLUSIVE: Ligand Subsidiary Pelthos Therapeutics To Combine with Channel Therapeutics Creating Pain Medicines Focused Entity

All NewsApril 17, 2025

Ligand and Channel Therapeutics to merge in $50 million deal to launch Zelsuvmi for molluscum and advance NaV 1.7 chronic pain programs.

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.

Cookie settings ACCEPT

EXCLUSIVE: Ligand Subsidiary Pelthos Therapeutics To Combine with Channel Therapeutics Creating Pain Medicines Focused Entity

The UCW Newswire : Financial, Business and Tech News

Recent Headlines

JCPenney makes big move to win back holiday shoppers after store closures

Mark Cuban says get your cash ready for this change — ‘That’s when the real money is made’

Airfares are up 22.4% compared to this time last year and show no sign of easing

Bank of America has unexpected verdict on AI stocks after post-midterm Democrat sweep

39-year-old travel agency shuts down in bankruptcy, cancels all flights